Compare STG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STG | IMUX |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | N/A | 66 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.1M | 209.2M |
| IPO Year | 2017 | 2013 |
| Metric | STG | IMUX |
|---|---|---|
| Price | $3.52 | $13.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 7.0K | ★ 135.8K |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $0.51 |
| 52 Week High | $11.53 | $15.84 |
| Indicator | STG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 35.19 |
| Support Level | $3.60 | $11.21 |
| Resistance Level | $4.77 | $13.30 |
| Average True Range (ATR) | 0.11 | 0.89 |
| MACD | -0.04 | -0.33 |
| Stochastic Oscillator | 21.21 | 2.68 |
Sunlands Technology Group operates in China's adult online education market and adult personal interest learning market through its online platforms. The Group has a deep understanding of the educational needs of its prospective students and offers solutions to help them achieve their goals. It provides online professional courses and educational content, including interest, professional skills, professional certification preparation courses, and degree- or diploma-oriented post-secondary courses. The Group adopts a counseling-oriented sales and marketing approach to offer education solutions based on students' backgrounds and goals, delivering adult online education and personal interest learning through extensive course and content offerings.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.